Get ARS Pharmaceuticals alerts:ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) – Investment analysts at William Blair cut their FY2025 EPS estimates for shares of ARS Pharmaceuticals in a research report issued on Tuesday, September 30th. William Blair also issued estimates for ARS Pharmaceuticals’ Q4 2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.76) EPS. Raymond James Financial set a $32.00 target price on ARS Pharmaceuticals in a research note on Friday, September 26th. ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. Featured StoriesReceive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.